Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7988)	12/8/1998 11:19:00 PM
From: Tharos	Read Replies (1) \| Respond to of 17367

Tell a man that there are 400 billion stars and he'll believe you. Tell him a bench has wet paint and he has to touch it.

To: Robert S. who wrote (7988)	12/9/1998 1:06:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

RobertS, Amgen used the concept for subsidiaries. You will note the famed Al Bundy correctly stated that a subsidiary was not the same as changing ones domicile and that there were no other biotecks listed as having domicile in Bermuda. To the extent that anything is new, it appears to me that Lehman has packaged the concept and has been or will be presenting it to potential clients. I think other investment bankers will implement their own versions. Now even if investment bankers have been presenting this idea for some time, what is new is that the concept really seems to fit a specific industry group, biotechs with recently approved products or those in P III trials. If you don't agree with me that"s fine. If you don't understand me, that's also fine. However please, don't misrepresent what I have said.